Rudin, Charles M. http://orcid.org/0000-0001-5204-3465
Poirier, John T. http://orcid.org/0000-0001-9795-5644
Byers, Lauren Averett
Dive, Caroline http://orcid.org/0000-0002-1726-8850
Dowlati, Afshin
George, Julie
Heymach, John V.
Johnson, Jane E.
Lehman, Jonathan M.
MacPherson, David
Massion, Pierre P.
Minna, John D.
Oliver, Trudy G.
Quaranta, Vito
Sage, Julien http://orcid.org/0000-0002-8928-9968
Thomas, Roman K.
Vakoc, Christopher R.
Gazdar, Adi F.
Article History
First Online: 29 March 2019
Change Date: 7 June 2019
Change Type: Correction
Change Date: 27 June 2019
Change Type: Update
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Change Details: An author correction to Supplementary Table 1 was made, but the original file was not updated. We have now updated Supplementary Table 1 in the original article.
Competing interests
: C.M.R. has consulted for AbbVie, Amgen, Ascentage, AstraZeneca, BMS, Celgene, Daiichi Sankyo, Genentech/Roche, Ipsen, Loxo and PharmaMar; is on the scientific advisory board for Elucida and Harpoon; and receives research funding from Daiichi Sankyo. L.A.B. has consulted for AbbVie, AstraZeneca, BerGenBio, Genmab and PharmaMar and receives research support from AbbVie, AstraZeneca, Genmab and Tolero. C.D. has consulted for AstraZeneca and Merck and receives research funding from AstraZeneca, Epigene, Amgen, FLX Bio, Menarini and Angel. J.V.H. has consulted for AstraZeneca, Boehringer Ingelheim, Exelixis, Genentech, GlaxoSmithKline, Guardant, Hengrui, Lilly, Novartis, Spectrum, EMD Serono and Synta; has received research support from AstraZeneca, Bayer, GlaxoSmithKline and Spectrum; and receives royalties and licensing fees from Spectrum. J.M.L. receives research funding from Ipsen and AbbVie. D.M. received research funding from Janssen and Roche. J.D.M. and A.F.G. receive licensing royalties for cell lines from the US National Institutes of Health and the University of Texas Southwestern Medical Center. J.S. receives research funding from AbbVie. C.R.V. is an adviser to KSQ Therapeutics. All other authors declare no competing interests.